HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains

Vaccine

Volumn 30, Issue 35, 2012, Pages 5262-5269

  Luytjes, Willem ^a   Enouf, Vincent ^b,c,d   Schipper, Maarten ^a   Gijzen, Karlijn ^a   Liu, Wai Ming ^a   van der Lubben, Mariken ^a   Meijer, Adam ^a   van der Werf, Sylvie ^b,c,d   Soethout, Ernst C ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b INSTITUT PASTEUR   (France)

^c CNRS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Clinical study; Cross specific immunity; Hemagglutination inhibition; Influenza; Vaccination

Indexed keywords

INFLUENZA VACCINE;

ADULT; ARTICLE; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SEASONAL INFLUENZA;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; COHORT STUDIES; CROSS PROTECTION; FEMALE; FOLLOW-UP STUDIES; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, HUMORAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LOGISTIC MODELS; MALE; MIDDLE AGED; PANDEMICS; VACCINATION; YOUNG ADULT;

EID: 84863854373     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.060     Document Type: Article

References (39)

1. [16.01.11]. http://www.who.int/mediacentre/factsheets/fs211/en/index.html.
2. Murasko D.M., Bernstein E.D., Gardner E.M., Gross P., Munk G., Dran S., et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002, 37:427-439.
3. McElhaney J.E. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005, 23(Suppl. 1):S10-S25.
4. Ikonen N., Strengell M., Kinnunen L., Osterlund P., Pirhonen J., Broman M., et al. High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill 2010, 15.
5. Donaldson L.J., Rutter P.D., Ellis B.M., Greaves F.E., Mytton O.T., Pebody R.G., et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 2009, 339:b5213.
6. Reed C., Angulo F.J., Swerdlow D.L., Lipsitch M., Meltzer M.I., Jernigan D., et al. Estimates of the prevalence of pandemic (H1N1) 2009, United States, April-July 2009. Emerg Infect Dis 2009, 15:2004-2007.
7. Cox N.J., Fukuda K. Influenza. Infect Dis Clin North Am 1998, 12:27-38.
8. Adalja A.A., Henderson D.A. Original antigenic sin and pandemic (H1N1) 2009. Emerg Infect Dis 2010, 16:1028-1029.
9. Davenport F.M., Hennessy A.V., Francis T. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med 1953, 98:641-656.
10. Morens D.M., Burke D.S., Halstead S.B. The wages of original antigenic sin. Emerg Infect Dis 2010, 16:1023-1024.
11. Johns M.C., Eick A.A., Blazes D.L., Lee S.E., Perdue C.L., Lipnick R., et al. Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel. PLoS ONE 2010, 5:e10722.
12. Viboud C., Simonsen L. Does seasonal influenza vaccination increase the risk of illness with the 2009 A/H1N1 pandemic virus?. PLoS Med 2010, 7:e1000259.
13. Janjua N.Z., Skowronski D.M., Hottes T.S., Osei W., Adams E., Petric M., et al. Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: first detection of the association in British Columbia, Canada. Clin Infect Dis 2010, 51:1017-1027.
14. Pelat C., Falchi A., Carrat F., Mosnier A., Bonmarin I., Turbelin C., et al. Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A(H1N1) influenza: estimations from surveillance data in France. PLoS ONE 2011, 6:e19621.
15. Hannoun C., Megas F., Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004, 103:133-138.
16. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24:1159-1169.
17. Gravenstein S.B., Miller B., Ershler W., Brown C., Mast E., Circo R., et al. Low sensitivity of CDC case definition for H3N2 influenza in elderly nursing home subjects. Clin Res 1990, 38:547A.
18. van Gageldonk-Lafeber A.B., Heijnen M.L., Bartelds A.I., Peters M.F., van der Plas S.M., Wilbrink B. A case-control study of acute respiratory tract infection in general practice patients in The Netherlands. Clin Infect Dis 2005, 41:490-497.
19. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011, 28:2731-2739.
20. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999, 41:95-98.
21. Ballet C., Roussey-Kesler G., Aubin J.T., Brouard S., Giral M., Miqueu P., et al. Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am J Transplant 2006, 6:2796-2801.
22. Boge T., Remigy M., Vaudaine S., Tanguy J., Bourdet-Sicard R., van der W.S. A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials. Vaccine 2009, 27:5677-5684.
23. R Development Core Team. A language and environment for statistical computing. Vienna; 2011.
24. Survival analysis, including penalised likelihood [computer program]. Version 2 2011, p. 36-9.
25. Rigby R.A., Stasinopoulos D.M. Generalized additive models for location, scale and shape. Appl Stat 2005, 54:507-554.
26. Fay M.P. Confidence intervals that match Fisher's exact or Blaker's exact tests. Biostatistics 2010, 11:373-374.
27. Euroflu - Influenza database. [25.05.11]. http://www%20euroflu%20org/cgi-files/graphs_public%20cgi.
28. de Jong J.C., Rimmelzwaan G.F., Donker G.A., Meijer A., Fouchier R.A., Osterhaus A.D. The 2006/'07 influenza season in the Netherlands and the vaccine composition for the 2007/'08 season. Ned Tijdschr Geneeskd 2007, 151:2158-2165.
29. Petrie J.G., Ohmit S.E., Johnson E., Cross R.T., Monto A.S. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis 2011, 203:1309-1315.
30. Smith D.J., Lapedes A.S., de Jong J.C., Bestebroer T.M., Rimmelzwaan G.F., Osterhaus A.D., et al. Mapping the antigenic and genetic evolution of influenza virus. Science 2004, 305:371-376.
31. Al-Khayatt R., Jennings R., Potter C.W. Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis. J Hyg (Lond) 1984, 93:301-312.
32. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972, 70:767-777.
33. Coudeville L., Bailleux F., Riche B., Megas F., Andre P., Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med Res Methodol 2010, 10:18.
34. Jhung M.A., Swerdlow D., Olsen S.J., Jernigan D., Biggerstaff M., Kamimoto L., et al. Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin Infect Dis 2011, 52(Suppl. 1):S13-S26.
35. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361:1945-1952.
36. Kilbourne E.D., Smith C., Brett I., Pokorny B.A., Johansson B., Cox N. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci U S A 2002, 99:10748-10752.
37. Nelson M.I., Viboud C., Simonsen L., Bennett R.T., Griesemer S.B., St G.K., et al. Multiple reassortment events in the evolutionary history of H1N1 influenza A virus since 1918. PLoS Pathog 2008, 4:e1000012.
38. Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009, 9:185-194.
39. Frasca D., Landin A.M., Riley R.L., Blomberg B.B. Mechanisms for decreased function of B cells in aged mice and humans. J Immunol 2008, 180:2741-2746.